Mutational alteration of the p16CDKN2a tumor suppressor gene is infrequent in Ewing's sarcoma.

Y. K. Park, Sung-Gil Chi, Y. W. Kim, H. R. Park, K. K. Unni

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Mutational alteration of the p16CDKN2a tumor suppressor gene has been frequently observed in a variety of human cell lines and tumor tissues. To assess whether alterations of the p16CDKN2a gene play an important role in the pathogenesis of Ewing's sarcoma, we examined the allelic deletion and point mutation of the gene in 27 primary tumors. In quantitative DNA/PCR analysis for three individual exons of the gene, none of the 27 specimens showed detectable reduction in the amplification levels compared to those of normal lymphocytes. To explore the presence of any subtle sequence changes within the protein coding region, we performed a comprehensive screening of sequence alteration in the three exons using DNA/PCR-SSCP analysis. However, no abnormal shift of SSCP bands indicative of sequence change was identified. In addition, no elevation of p16CDKN2a mRNA expression was observed in the RD-ES cell line following 5'-Aza-cytidine treatment, indicating that the promoter of the gene is not abnormally methylated in this cell line. Immunohistochemical study of the same tissue specimens for p16CDKN2a and pRB also revealed grade 2+ or 3+ nuclear staining of both proteins in most of the specimens we examined. Taken together, our results strongly suggest that the mutational inactivation of the p16CDKN2a gene might be a rare event, and thus not play a critical role in the pathogenesis of Ewing's sarcoma.

Original languageEnglish
Pages (from-to)1261-1266
Number of pages6
JournalOncology Reports
Volume6
Issue number6
Publication statusPublished - 1999 Nov 1
Externally publishedYes

Fingerprint

Ewing's Sarcoma
Tumor Suppressor Genes
Single-Stranded Conformational Polymorphism
Genes
Exons
Cell Line
Cytidine
Polymerase Chain Reaction
Sequence Deletion
DNA
Gene Silencing
Tumor Cell Line
Point Mutation
Open Reading Frames
Lymphocytes
Staining and Labeling
Messenger RNA
Neoplasms
Proteins

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Mutational alteration of the p16CDKN2a tumor suppressor gene is infrequent in Ewing's sarcoma. / Park, Y. K.; Chi, Sung-Gil; Kim, Y. W.; Park, H. R.; Unni, K. K.

In: Oncology Reports, Vol. 6, No. 6, 01.11.1999, p. 1261-1266.

Research output: Contribution to journalArticle

Park, YK, Chi, S-G, Kim, YW, Park, HR & Unni, KK 1999, 'Mutational alteration of the p16CDKN2a tumor suppressor gene is infrequent in Ewing's sarcoma.', Oncology Reports, vol. 6, no. 6, pp. 1261-1266.
Park, Y. K. ; Chi, Sung-Gil ; Kim, Y. W. ; Park, H. R. ; Unni, K. K. / Mutational alteration of the p16CDKN2a tumor suppressor gene is infrequent in Ewing's sarcoma. In: Oncology Reports. 1999 ; Vol. 6, No. 6. pp. 1261-1266.
@article{96870b75e63f4d5396bfe640711d17f8,
title = "Mutational alteration of the p16CDKN2a tumor suppressor gene is infrequent in Ewing's sarcoma.",
abstract = "Mutational alteration of the p16CDKN2a tumor suppressor gene has been frequently observed in a variety of human cell lines and tumor tissues. To assess whether alterations of the p16CDKN2a gene play an important role in the pathogenesis of Ewing's sarcoma, we examined the allelic deletion and point mutation of the gene in 27 primary tumors. In quantitative DNA/PCR analysis for three individual exons of the gene, none of the 27 specimens showed detectable reduction in the amplification levels compared to those of normal lymphocytes. To explore the presence of any subtle sequence changes within the protein coding region, we performed a comprehensive screening of sequence alteration in the three exons using DNA/PCR-SSCP analysis. However, no abnormal shift of SSCP bands indicative of sequence change was identified. In addition, no elevation of p16CDKN2a mRNA expression was observed in the RD-ES cell line following 5'-Aza-cytidine treatment, indicating that the promoter of the gene is not abnormally methylated in this cell line. Immunohistochemical study of the same tissue specimens for p16CDKN2a and pRB also revealed grade 2+ or 3+ nuclear staining of both proteins in most of the specimens we examined. Taken together, our results strongly suggest that the mutational inactivation of the p16CDKN2a gene might be a rare event, and thus not play a critical role in the pathogenesis of Ewing's sarcoma.",
author = "Park, {Y. K.} and Sung-Gil Chi and Kim, {Y. W.} and Park, {H. R.} and Unni, {K. K.}",
year = "1999",
month = "11",
day = "1",
language = "English",
volume = "6",
pages = "1261--1266",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "6",

}

TY - JOUR

T1 - Mutational alteration of the p16CDKN2a tumor suppressor gene is infrequent in Ewing's sarcoma.

AU - Park, Y. K.

AU - Chi, Sung-Gil

AU - Kim, Y. W.

AU - Park, H. R.

AU - Unni, K. K.

PY - 1999/11/1

Y1 - 1999/11/1

N2 - Mutational alteration of the p16CDKN2a tumor suppressor gene has been frequently observed in a variety of human cell lines and tumor tissues. To assess whether alterations of the p16CDKN2a gene play an important role in the pathogenesis of Ewing's sarcoma, we examined the allelic deletion and point mutation of the gene in 27 primary tumors. In quantitative DNA/PCR analysis for three individual exons of the gene, none of the 27 specimens showed detectable reduction in the amplification levels compared to those of normal lymphocytes. To explore the presence of any subtle sequence changes within the protein coding region, we performed a comprehensive screening of sequence alteration in the three exons using DNA/PCR-SSCP analysis. However, no abnormal shift of SSCP bands indicative of sequence change was identified. In addition, no elevation of p16CDKN2a mRNA expression was observed in the RD-ES cell line following 5'-Aza-cytidine treatment, indicating that the promoter of the gene is not abnormally methylated in this cell line. Immunohistochemical study of the same tissue specimens for p16CDKN2a and pRB also revealed grade 2+ or 3+ nuclear staining of both proteins in most of the specimens we examined. Taken together, our results strongly suggest that the mutational inactivation of the p16CDKN2a gene might be a rare event, and thus not play a critical role in the pathogenesis of Ewing's sarcoma.

AB - Mutational alteration of the p16CDKN2a tumor suppressor gene has been frequently observed in a variety of human cell lines and tumor tissues. To assess whether alterations of the p16CDKN2a gene play an important role in the pathogenesis of Ewing's sarcoma, we examined the allelic deletion and point mutation of the gene in 27 primary tumors. In quantitative DNA/PCR analysis for three individual exons of the gene, none of the 27 specimens showed detectable reduction in the amplification levels compared to those of normal lymphocytes. To explore the presence of any subtle sequence changes within the protein coding region, we performed a comprehensive screening of sequence alteration in the three exons using DNA/PCR-SSCP analysis. However, no abnormal shift of SSCP bands indicative of sequence change was identified. In addition, no elevation of p16CDKN2a mRNA expression was observed in the RD-ES cell line following 5'-Aza-cytidine treatment, indicating that the promoter of the gene is not abnormally methylated in this cell line. Immunohistochemical study of the same tissue specimens for p16CDKN2a and pRB also revealed grade 2+ or 3+ nuclear staining of both proteins in most of the specimens we examined. Taken together, our results strongly suggest that the mutational inactivation of the p16CDKN2a gene might be a rare event, and thus not play a critical role in the pathogenesis of Ewing's sarcoma.

UR - http://www.scopus.com/inward/record.url?scp=0033227484&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033227484&partnerID=8YFLogxK

M3 - Article

C2 - 10523693

AN - SCOPUS:0033227484

VL - 6

SP - 1261

EP - 1266

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 6

ER -